louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02765971: The Efficacy of Chewing Gums Versus Laxative in Early Return of Bowel Function After CS
Official title: The Efficacy of Chewing Gums Versus Laxatives in Early Return of Bowel Function After Cesarean Section
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Intestinal Recovery After Cesarean Section
Keywords: chewing gums
laxatives
bowel function
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2016-05-09
Enrollment: 540
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: 540 consented women for being enrolled in this clinical trial and candidates for elective cesarean section will be divided into 3 groups:

* Group A, 180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval.
* Group B, 180 women will receive laxatives after their operating room discharge by 3 hours.
* Group C, 180 women as control group, they will not receive neither gum nor oral fluids. They will be on intravenous fluid. starting oral fluids after hearing intestinal sounds .

Detailed description: 540 consented women for being enrolled in this clinical trial and candidates for elective cesarean section will be divided into 3 groups:

* Group A, 180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval.
* Group B, 180 women will receive laxatives after their operating room discharge by 3 hours.

Group C, 180 women as control group, they will not receive neither gum nor oral fluids. They will be on intravenous fluid. starting oral fluids after hearing intestinal sounds .

Eligibility criteria: Inclusion Criteria:

* all women undergoing elective cesarean section in Kasr Al AI Aini hospital will be candidate for this trial after full explanation of the trial and informed consent to be taken from the women.

Exclusion Criteria:

* cesarean hysterectomy,
* surgical management of severe postpartum hemorrhage
* previous bowel surgery
* women with history of drug consumption,especially opioids
* water and electrolyte disturbances
* pancreatitis or peritonitis
* inability to chew gum
* diabetes, pregnancies accompanied by coagulopathy like pre-eclampsia, hypothyroidism, muscular and neurological disorders
* postoperative admission to intensive care unit
* history of abdominal surgery except cesarean section
* history of postoperative ileus
* patients with drains

Primary outcomes:
measure: appearance of intestinal sounds postoperative evaluated by stethoscope
timeFrame: 4-6 hours after CS
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Kasr Alainy medical school
Study officials:
affiliation: Cairo University
name: Ahmed Maged
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04624971: A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era
Official title: A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Diffuse Large B Cell Lymphoma
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2020-11-12
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients with clinical information available

Brief summary: The purpose of this study is to determine the predictive value of a model of Nomogram Prognostic Index (NPI) in patients with Diffuse Large B cell lymphoma.


Eligibility criteria: Inclusion Criteria:

* histologically confirmed diagnosis of CD20+ DLBCL

Exclusion Criteria:

* primary central nervous system lymphoma
* "double-hit" lymphoma

Primary outcomes:
measure: Overall survival
timeFrame: 5-year
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Guangdong General Hospital
state: Guangdong
city: Guangzhou
country: China
facility: Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,
city: Guangzhou
country: China
facility: Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,
Study officials:
References:
Clinical trial NCT02859571: Continuous Versus Intermittent Oxytocin for Induction of Labor: A Randomized Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Intemittant, Continue, Oxytocin
Lead sponsor: Zeynep Kamil Maternity and Pediatric Research and Training Hospital
Sponsor class: OTHER
First posted: 2016-08-09
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates continuous oxytocin versus intermittent oxytocin for induction of labor at term. Half of participants will be taken continuous oxytocin, while the other half will be taken intermittent oxytocin.

Detailed description: In the continuous oxytocin group, traditional treatment of oxytocin used at a starting dose of 1-2 mIU/min and the dose was increased by 2 mIU/min at every 15 minutes until regular contractions obtained at a rate of 3-5 contractions in a 10-minute period. The maximum dose of oxytocin was 40 mIU/min and oxytocin was administered until delivery. In the intermittent group, oxytocin was discontinued when cervical dilation was 5 cm and 2 hours after discontinuation oxytocin was reused at a starting dose of 1-2 mIU/min and was increased as the same protocol used for continuation oxytocin group.

Eligibility criteria: Inclusion Criteria:

* singleton pregnancy,
* 37≤ weeks of gestational age ,
* vertex presentation,
* women with cervical dilation 3 cm
* no contraindication to vaginal delivery.

Exclusion Criteria:

* fetal malpresentation,
* multifetal pregnancy,
* more than three contractions in 10 minutes,
* contraindications to oxytocin,
* a category II or III fetal heart rate pattern,
* fetal anomaly,
* fetal demise
* women with immediate delivery indications

Primary outcomes:
measure: induction-to-delivery time
timeFrame: intraoperative
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Zeynep Kamil Maternity and Children's Training and Research Hospital, Department of Obstetrics and Gynecology
Study officials:
affiliation: Zeynep Kamil Maternity and Pediatric Research and Training Hospital
name: evrim bostanci ergen
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bor P, Ledertoug S, Boie S, Knoblauch NO, Stornes I. Continuation versus discontinuation of oxytocin infusion during the active phase of labour: a randomised controlled trial. BJOG. 2016 Jan;123(1):129-35. doi: 10.1111/1471-0528.13589. Epub 2015 Aug 26.
citation: Ozturk FH, Yilmaz SS, Yalvac S, Kandemir O. Effect of oxytocin discontinuation during the active phase of labor. J Matern Fetal Neonatal Med. 2015 Jan;28(2):196-8. doi: 10.3109/14767058.2014.906573. Epub 2014 Apr 9.
Clinical trial NCT00615771: Day of Embryo Transfer for Patients Undergoing In Vitro Fertilization
Official title: Embryo Transfer on Day 2 vs. Day 3 After Oocyte Retrieval in Patients Who Plan to Replace All Embryos After an In Vitro Fertilization Cycle
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2008-02-14
Enrollment: 242
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: We are examining whether pregnancy rates differ based on day of embryo transfer in patients who replace all available embryos after an In vitro Fertilization (IVF) cycle. Patients must be undergoing IVF treatment at Stanford University and patients will not receive compensation for their participation (no medical costs covered or patient payment for participation).

Detailed description: The decision on the number of embryos to transfer after an IVF cycle is based on the number of available embryos, the quality of the embryos, the patient's age, and the goal of limiting multiple gestations. Stanford Fertility Center and most IVF centers examine the embryos on the third day after oocyte (egg) retrieval to select for the best quality embryos to transfer, and depending on quality, the remaining embryos are frozen to be used in the future. Patients with a limited number of embryos, those that plan to replace all available embryos after an IVF cycle, do not need to wait until the third day after oocyte retrieval to select embryos, and may replace the embryos on the second day after the oocyte retrieval. We are examining whether pregnancy rates differ among these patients based on the day of embryo transfer (Day 2 vs. Day3). Patients must be undergoing IVF treatment at Stanford University and patients will not receive compensation for their participation (no medical costs covered or patient payment for participation).

Eligibility criteria: Inclusion Criteria:

Patients undergoing fresh IVF cycle at Stanford Fertility Center who plan on replacing all available embryos.

Exclusion Criteria:

Patients that do not meet above criteria.

Primary outcomes:
measure: Pregnancy rates
timeFrame: 1 year
Secondary outcomes:
measure: Live birth rates
timeFrame: 1 year
measure: Multiple gestation rates
timeFrame: 1 year
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Lora K Shahine
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05059171: Postoperative Pain of Rotary Versus Reciprocating Motions of Two Single Files
Official title: Postoperative Pain After Pulpectomy of Primary Molars Using With Rotary Versus Reciprocation Motions of Two Single Files: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Pain
Lead sponsor: Minia University
Sponsor class: OTHER
First posted: 2021-09-28
Enrollment: 260
Sex: ALL
Minimum age (years): 4
Maximum age (years): 8
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: An equivalent parallel randomized clinical trial was approved by the local University Committee of Ethics. 260 children with necrotic primary molars were allocated into 2 equal groups (82 children per group). The participants were allocated into two groups; group "1" teeth were instrumented with OneShape rotary system (Micro Mega, Besancon, France), and group "2" teeth were instrumented with WaveOne Gold reciprocating system (Dentsply Maillefer, Ballaigues, Switzerland). Postoperative pain was assessed using a four-point pain intensity rating scale adopted from Wong-Baker FACES (WBF) pain scale . The face scale consists of four faces with a brief title describing each face representing a scale from the first face (score 1), second face (score 2), third face (score 3), and forth face (score 4) 3. Postoperative pain was assessed at 6 six time intervals (at 6, 12, 24, 48, 72 hours and one-week).


Eligibility criteria: Inclusion Criteria:

1. Children ages from 4 to 8 years classified as class I or II according to the American Society of Anesthesiologists (ASA).
2. No previous dental experience.
3. Non-vital primary molar (necrotic or with chronic apical periodontitis) which confirmed radiographicly with the presence or absence of periapical radiolucency.
4. Severe tooth mobility.

Exclusion Criteria:

1. Severe behaviour or emotional disabilities.
2. Analgesic intake in the preceding 12 hours.
3. Non-restorable crowns of primary molars.
4. Radiographic presence of internal root resorption or massive bone destruction.
5. Root resorption exceeded one-third of the root length.

   -

Primary outcomes:
measure: Postoperative pain
timeFrame: One week
Secondary outcomes:
Other outcomes:
Locations:
city: Minya
country: Egypt
facility: Ngwa Khattab
state: Minia
Study officials:
References:
Clinical trial NCT01993771: Monitoring of Anaesthesic Depth in the Cerebral Cortex Using Bispectral Bilateral System.
Official title: Monitoring of Anaesthetic Depth at Different Locations in the Cerebral Cortex Using Bispectral Bilateral System
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Surgery
Lead sponsor: Parc de Salut Mar
Sponsor class: OTHER
First posted: 2013-11-25
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with alopecia scheduled for general anaesthesia.

Brief summary: This is a prospective, observational study, aimed to establish changes of bispectral bilateral system in both cerebral hemispheres during a total intravenous anaesthesia during breast surgery in the woman. By placing two Bispectral bilateral sensors (BIS), one on both frontal lobes, and another on both parietal lobes, we wanted to evaluate differences between frontal and parietal areas, when the patient is awake and during the anaesthetic procedure.


Eligibility criteria: Inclusion Criteria:

* Aged more than 18 years old.
* Scheduled for general anaesthesia.
* Agree to participate(signed inform consent).

Exclusion Criteria:

* Neurological disease.
* Cognitive impairment.
* Egg allergy.
* Severe disease or condition that could potentially interfere with interpretation of tests.

Primary outcomes:
measure: Bilateral BIS values from frontal and parietal areas.
timeFrame: Bilateral BIS values will be taken at baseline, anaesthetic induction, endotracheal intubation, skin incision, mantenance of anaesthesia and in emergence from anaesthesia ( 3 hours as a maximum from baseline to emergence).
Secondary outcomes:
measure: EEG changes at LOC (loss of consciousness) and ROC (recovery of consciousness).
timeFrame: Changes will be evaluated at induction and emergence.
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital del Mar
Study officials:
References:
Clinical trial NCT04062071: Use of Anticoagulant, and Associated Factors of Anticoagulant Refusal Atrial Fibrillation Patients
Official title: Prevalence of Use of Anticoagulant, and Associated Factors of Anticoagulant Refusal in Non-valvular Atrial Fibrillation Patients---- A Study in Hong Kong General Out-patient Clinic
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Atrial Fibrillation
Keywords: anticoagulants
Lead sponsor: Prince of Wales Hospital, Shatin, Hong Kong
Sponsor class: OTHER
First posted: 2019-08-20
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: all of the documented atrial fibrillation patients having regular follow up in GOPC in the study period

Brief summary: Atrial fibrillation is a clinically significant cardiac arrhythmia that increases the risk of stroke by 3 to 4 times. Oral anticoagulation has been shown to mitigate stroke risk by two-thirds among patients with AF and is widely recommended in optimizing AF management.Direct oral anticoagulants have also been demonstrated to be superior to warfarin with respect to the risk of fatal bleeding and stroke prevention.

However, the previous study finding highlighted a great gap between current guidelines and the clinical management of AF .Nonetheless, the decision for anticoagulant use is not straightforward.It is worth to investigate the updated prevalence of anticoagulant use, the reasons for not receiving anticoagulant, and the factors independently associated with anticoagulant refusal in patients with non-valvular atrial fibrillation.


Eligibility criteria: Inclusion Criteria:

* diagnosis as atrial fibrillation
* aged ≧18 years
* able to given consent

Exclusion Criteria:

* Unable/unwillingness to sign informed consent to study
* mechanical heart valve
* moderate-to-severe mitral stenosis
* Transient atrial fibrillation from reversible cause (e.g., during respiratory tract infection or bronchospasm)
* pregnancy
* hospitalization within 1 month prior to inclusion in the study.

Primary outcomes:
measure: The prevalence of anticoagulant use in non-valvular atrial fibrillation patients
timeFrame: August 2019 to March 2020
Secondary outcomes:
measure: the rate of the refusal of anticoagulant use
timeFrame: August 2019 to March 2020
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: LIAO, Jiawei
Study officials:
References:
Clinical trial NCT06343571: Longitudinal Outcomes in MED-EL Cochlear Implant Recipients Using a FLEX Electrode
Official title: Longitudinal Outcomes in MED-EL Cochlear Implant Recipients Using a FLEX Electrode Array: a Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cochlear Implants
Keywords: cochlear implants
Lead sponsor: MED-EL Elektromedizinische Geräte GesmbH
Sponsor class: INDUSTRY
First posted: 2024-04-02
Enrollment: 2000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: There is no requirement to actively participate in the study for any of the subjects.

This study consists of a one-time data extraction from a clinical database. Data will be included from 03/2006 to date of extraction

Brief summary: This retrospective study aims at analysing data from clinical routine as anonymized data sets. The study aims at analysing clinical data from MED-EL Cochlear Implant (CI) recipients using a FLEX electrode array.


Eligibility criteria: Inclusion Criteria:

* MED-EL CI recipients
* FLEX electrode array

Exclusion Criteria:

* Lack of compliance with any inclusion criterion

Primary outcomes:
measure: Evaluate short and long term longitudinal clinical performance data from MED-EL CIs to assess their clinical effectiveness and safety.
timeFrame: Through study completion: single data extraction (3 month to completion)
Secondary outcomes:
Other outcomes:
Locations:
city: Hanover
country: Germany
facility: Hannover Medical School
Study officials:
affiliation: Hannover Medical School
name: Andreas Büchner, Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05445271: Optic Nerve Sheath Diameter in Pediatric Patients
Official title: The Effects of Endotracheal Intubation or Laryngeal Mask Applications on Optic Nerve
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Optic Nerve Sheath Neoplasm
Intracranial Pressure Increase
Intubation Complication
Airway Complication of Anesthesia
Lead sponsor: Kahramanmaras Sutcu Imam University
Sponsor class: OTHER
First posted: 2022-07-06
Enrollment: 90
Sex: ALL
Minimum age (years): 2
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Endotracheal intubation and laryngeal mask are generally applied to secure the airway during general anesthesia. There is a widespread opinion among anesthesiologists that endotracheal intubation increases intracranial pressure. Since there were no non-invasive methods measuring intracranial pressure in the past, adequate studies on this subject could not be done. With this measurement, we aimed to show whether ETT or LMA applications have effects on intracranial pressure.

Detailed description: In normal pediatric patients with closed fontanelles, the contents of the central nervous system are almost compressed into the skull and spinal canal. Intracranial pressure is created and constant by the total volume of brain, CSF, and blood within the skull. Increased intracranial pressure can be measured with an intraventricular catheter, transducers, and a subarachnoid bolt. By measuring the diameter of the optic nerve sheath with ultrasonography, we can find out whether there is an increase in intracranial pressure non-invasively.

Endotracheal intubation and laryngeal mask are generally applied to secure the airway during general anesthesia. There is a widespread opinion among anesthesiologists that endotracheal intubation increases intracranial pressure. Since there were no non-invasive methods measuring intracranial pressure in the past, adequate studies on this subject could not be done. With this measurement, we aimed to show whether ETT or LMA applications have effects on intracranial pressure.

Eligibility criteria: Inclusion Criteria:

1. Patients aged 2-18 years
2. Patients undergoing general anesthesia
3. Patients who agreed to be included
4. ASA I-III

Exclusion Criteria:

1. Those with any eye pathology
2. Those with intracranial pathology

Primary outcomes:
measure: Optic nerve sheath diameter measurement at pediatric patients
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00705471: Impact of Infliximab in Fistulizing Crohn's Disease on Health Care Resources (Study P04204)(TERMINATED)
Official title: Infliximab Use in Fistulizing Crohn's Disease: Impact on Health Care Resources
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Crohn Disease
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
Collaborators: name: Centocor, Inc.
First posted: 2008-06-26
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The charts of subjects with fistulizing CD to be recorded for the time period for up to three years before and for one year after their initial infliximab infusion for comparison of health care costs and utilization prior to infliximab and post infliximab use.

Brief summary: A multi-centre retrospective review of fistulizing Crohn's disease (CD) patient charts will capture data to measure health care resource utilization associated with the use of Infliximab for treatment of CD. Three health science centres/hospitals from Ontario are targeted to participate in the study, each site is expected to provide 30-40 patient charts with a target of 108 charts total.

Detailed description: This study population was chosen from a non-probability sample.

Eligibility criteria: Inclusion Criteria:

* Treatment with infliximab for fistulizing CD.
* Administration of at least one infliximab infusion \>=12 months before the chart review.
* 18 years of age or over (men and women).

Exclusion Criteria:

* Subjects not followed for a full year after their first infusion of infliximab.
* Subjects not followed for a full year prior to their first infusion of infliximab.
* Subjects who had participated in clinical studies during the data collection timeframe.

Primary outcomes:
measure: To quantify the impact of infliximab therapy on the Canadian healthcare resource utilization as expressed as incidence per year.
timeFrame: 1 year
Secondary outcomes:
measure: To quantify the impact of infliximab therapy on healthcare resource utilization as expressed in Canadian dollars.
timeFrame: 1 year
Other outcomes:
Locations:
Study officials:
References: